Objective: To describe clinical experience with palladium 103 ( 103 Pd) ophthalmic plaque radiotherapy for choroidal hemangioma.
ment. Three patients (60%) demonstrated improvement in visual acuity at the last follow-up, and in 1 patient vision remained stable with resolution of metamorphopsia. Twenty-four months after treatment, 1 patient whose visual acuity had recovered from 20/160 to 20/32 had a loss of vision to 20/160 because of radiation maculopathy. For all patients, a mean visual acuity improvement of 2 lines was documented (95% confidence interval, 0.23-0.88). Mean follow-up was 18.6 months (range, 6-29 months).
Conclusions:
A single 103 Pd plaque radiation treatment was effective in decreasing tumor height, eliminating subretinal fluid, and improving visual acuity in patients with symptomatic circumscribed choroidal hemangiomas.
Arch Ophthalmol. 2004; 122:1652 -1656 C IRCUMSCRIBED CHOROIdal hemangioma is a benign vascular tumor that typically appears as a subtle, amelanotic, redorange mass in the posterior pole. 1 Mild yellow-white foci on the tumor surface may be present and represent fibrous metaplasia of the overlying retinal pigment epithelium. 2 Visual acuity loss typically results from intraretinal edema, cystoid degeneration, and accumulation of subretinal fluid. Massive exudation may lead to serous retinal detachment. 3 Various treatment modalities have been described for symptomatic choroidal hemangiomas and have included penetrating diathermy, xenon photocoagulation, argon laser photocoagulation, microwave hyperthermia, external beam radiotherapy, infrared diode laser thermotherapy, photodynamic therapy, stereotactic radiotherapy, and radioactive plaque therapy. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Laser photocoagulation was previously widely used to treat choroidal hemangiomas. The photocoagulation was scattered over the tumor's surface to reduce associated subretinal fluid. 5 Because of recur-rence of retinal detachments, multiple treatments were required and the long-term visual prognosis was poor. [3] [4] [5] More recently, various researchers have reported successful treatments of symptomatic circumscribed choroidal hemangiomas by photodynamic therapy (PDT). [6] [7] [8] [15] [16] [17] [18] [19] [20] Several researchers have also reported successful treatment of diffuse and circumscribed choroidal hemangiomas with radiation therapy. 9, 10, 12, 13 In 1996, Zographos et al 9 investigated cobalt 60 ( 60 Co) brachytherapy and suggested that radiotherapy was the best therapeutic modality for the treatment of large hemangiomas, those that involve the macular area, and hemangiomas associated with a bullous secondary exudative retinal detachment. Madreperla et al 10 tion of subretinal fluid in all patients and suggested that stereotactic therapy be targeted to small and posteriorly located circumscribed choroidal hemangiomas. 14 In 1989, palladium 103 ( 103 Pd) seeds became available for brachytherapy. 21 Comparative studies have shown that whenequivalenttargetdoseswereprescribed,theuseof 103 Pd resulted in an increased dose within the targeted zone (tumor) and less radiation to most normal ocular tissues comparedwith 125 I. 22 An11-yearstudyof 103 Pdplaqueradiotherapy for choroidal melanoma found better visual function outcomes compared with the results from centers using 125 I. 23 Herein are reported what we believe to be the first visual and anatomic results of a series of patients with symptomatic choroidal hemangiomas treated with 103 Pd ophthalmic plaque radiotherapy.
METHODS

PATIENT SELECTION
A prospective, nonrandomized clinical study was conducted in 5 consecutive patients with previously untreated and symptomatic circumscribed choroidal hemangioma. The diagnosis was made by clinical ophthalmoscopic, fluorescein angiographic, and ultrasonographic features. Each patient participated in a detailed discussion of the risks and benefits of various therapeutic modalities. All patients signed a statement of informed consent. Institutional review board approval was not considered necessary because of the established use of radiation therapy for choroidal hemangiomas.
DIAGNOSIS
Clinical history included the patient's age, sex, and medical history. Ophthalmic evaluations included a best-corrected visual acuity and pupillary, oculomotor, and slitlamp examinations. Goldmann tonometry was used to measure intraocular pressure. The basal dimensions of the tumors were determined by ophthalmoscopy, fluorescein angiography, transillumination, and B-scan ultrasonography. A-scan ultrasonography was used to measure the height of the tumor and internal reflectivity. Bscan ultrasonography was typically used to determine tumor location and shape and evidence of retinal detachments. Fluorescein angiography and fundus photography were used to evaluate and record patterns of tumor circulation, focal leakage, cystoid macular edema, and radiation retinopathy.
STATISTICAL ANALYSIS
The clinical data were analyzed with regard to improvement in visualacuityaftertreatment.TheSPSSsoftwarepackage,version11.01 (SPSS Inc, Chicago, Ill), was used for data analysis. The modified Wald test was used to calculate 95% confidence interval. with a thin layer of medical-grade acrylic fixative. Because of low energy of x-rays from 103 Pd, the 0.5-mm-thick plaque blocked more than 99% of photons directed to the sides of and posterior to the plaque. 22 Our methods of 103 Pd plaque dosimetry have been described elsewhere. 22, 23 In this series, all patients received 1 radiation treatment. Eye plaques were sewn to the episclera to cover the base of the intraocular tumor, radiation was continuously delivered during 2 to 5 days, and the plaques were removed. The tumor apex served as the radiation prescription point. Treatment time and dose rate were calculated on the basis of the dimensions of the tumors and followed COMS guidelines, whereby the apex dose rate was kept between 50 and 125 cGy/h (50 and 125 rad/h). Similarly, a treatment margin of 2 mm was included around the edges of the tumor. The mean apex dose for the 5 patients who were treated with 103 Pd was 2900 cGy (2900 rad) ( Table 1) . 
PALLADIUM 103 OPHTHALMIC PLAQUE RADIOTHERAPY
RESULTS
Five patients with symptomatic circumscribed choroidal hemangiomas were treated by 103 Pd brachytherapy. The mean age in this group was 55 years (range, 45-70 years). Follow-up was documented during a mean interval of 18.6 months (range, 6-29 months). The mean height of all tumors was 3.3 mm as measured by ultrasound (range, 2.5-4.0 mm) ( Table 2 ). All tumors decreased in height (to a mean of 1.7 mm) ( Figure) . No tumor recurrence was noted.
All tumor-associated retinal detachments resolved within the reported follow-up period (Figure) . Visual acuity improved in 4 (80%) of 5 patients after treatment, and 1 patient's visual acuity remained stable at 20/32 (with resolution of metamorphopsia). Twentyfour months after treatment, 1 patient whose visual acuity had recovered from 20/160 to 20/32 had a loss of vision to 20/160 because of radiation maculopathy. At the last follow-up, 3 patients (60%) retained their postoperative best-corrected visual acuity. For all patients, a mean visual acuity improvement of 2 lines was documented (95% confidence interval, 0.23-0.88) ( Table 2) . Compared with the results after other radiotherapy techniques, no new complications could be attributed to the use of 103 Pd.
COMMENT
Circumscribed choroidal hemangioma is a vascular tumor that can cause permanent loss of vision by leakage of subretinal fluid, associated retinal detachment, and cystoid degenerationoftheretina. 4 Managementbecomesmoreproblematic with large or anteriorly located tumors, lesions associated with extensive bullous retinal detachment, or tumors located in proximity to the optic nerve or fovea.
Laser photocoagulation will typically reduce the exudative subretinal fluid, but recurrences are common and associated with vision loss. 5 Recently, Schmidt-Erfurth et al, 7, 8 Madreperla, 6 Robertson, 15 andotherresearchershavereported on PDT in treatment of symptomatic circumscribed choroidal hemangiomas. [16] [17] [18] [19] [20] On average, 2 PDT treatments were required to control exudation of subretinal fluid. Overall, 60 patients were treated and 51 had an improvement in visual acuity (mean, 3.3 lines) after PDT ( Table 3) . Tumors were noted to decrease from a mean pretreatment tumor height of 3.0 mm to 0.4 mm at the last follow-up measurement. It is important to note that problems associated with PDT for large vascular lesions have included focal overtreatment, leading to chorioretinal atrophy and resultant visual field defects. 8 Photodynamic therapy is not practical for treatment of large or anteriorly located hemangiomas. Clearly, PDT relies on the visualization of the hemangioma to aim 
